Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?

At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma.

Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news